Alpha Tau reports 100% response rate for Alpha DaRT plus Keytruda in head and neck cancer study

• Alpha Tau reported positive results from a study of Alpha DaRT with Merck’s Keytruda in elderly patients with advanced head and neck cancer.
• Results were presented in a podium session at the American Head and Neck Society meeting in Boston on July 21, 2026.
• All evaluable patients responded to treatment, beating the trial’s pre-set success bar and supporting the company’s combination strategy in metastatic disease.
• Safety appeared manageable, with no serious side effects attributed to Alpha DaRT reported in the treated group.
• Recruitment is complete; the company is discussing a similar, larger U.S. study with the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-079822), on July 21, 2026, and is solely responsible for the information contained therein.